Seegene Inc

Seegene participates in EUROGIN 2017

Oct 17, 2017

Seegene participated in EUROGIN 2017 (European Research Organization on Genital Infection and Neoplasia), which was held in Amsterdam from October 8 through 11.

Comprised of eight clinical science workshops, this year’s program covered a diverse range of issues, including the effect of human papillomavirus (HPV) vaccine programs and vaccination guidelines, and recent developments in screening, prevention and management of cervical cancer, HPV infection and other cancers including vulvar, anal and head & neck HPV induced diseases for clinicians and research scientists.

At the congress, Seegene presented its Anyplex™ II HPV28 Detection, which effectively screens for HPV (the causal factor of cervical cancer), and Anyplex™ II HPV HR Detection product lines. And poster and oral presentation of clinical assessment results of these products has given by Seegene’s major customers from Spain, France and Norway.

Spain’s Institut Catala d'Oncologia (ICO), which is known as the most authoritative cancer research institution in Europe, especially, presented the results of their comparative research on the existing screening method (SPF10-DEIA-LiPA25) and Seegene’s Anyplex™ II HPV28 in conducting head and neck cancer screenings using oropharyngeal FFPE, with the latter demonstrating a much higher outcome concordance rate. This result is significant because it shows that the Anyplex™ II HPV28, which is already being used to screen for cervical cancer, can also be used to screen for head and neck cancer. Moreover, Dr. Hantz S. (France) presented a poster on research outcomes showing the outstanding result reproducibility and high accuracy of the Anyplex™ II HPV 28.

The Anyplex™ II HPV HR was also mentioned in symposium presentations by Dr. Marc Arbyn (Belgium), an authority in the HPV genotype screening sector, and Dr. Jesper Bonde (Denmark) as one of seven products that passes international guidelines on cervical cancer screening tests while also has proven screening accuracy and clinical effectiveness through a VALGENT study. These studies emphasized the fact that the Anyplex™ II HPV HR simultaneously offers HPV screening and HPV genotype data.

EUROGIN is an international congress that is focused on sharing information on clinical research, epidemiological surveys and the latest screening methods on HPV infections and cervical cancer screening/prevention. This year’s host country, the Netherlands, was one of the first countries to conduct a comprehensive national HPV screening program and remains at the forefront of early discovery and prevention of, as well as fundamental research on, HPV.

*Head and neck cancer
A collective term for the cancers that begin in the tissues and organs of the head and neck (composed of the oral cavity, pharynx and larynx), head and neck cancer includes oropharyngeal cancer, oral cancer and tonsil cancer. HPV, the major cause of cervical cancer, is known to also have a significant influence on the occurrence of head and neck cancer